On March 11th, "Focus on the Two Sessions · 2026 6th Ophthalmology Summit" was held in Beijing, featuring discussions on cutting-edge topics and the latest advancements in ophthalmology. Dr. Liu Datao, the representative of the enterprise side, was invited to participate in the panel discussion and shared insightful perspectives on innovative drug development and industrialization in the ophthalmology field.

The panel discussion, hosted by Professor Yuan Jin from Beijing Tongren Hospital, Capital Medical University (CMU), focused on key challenges in ophthalmology drug innovation including R&D of ophthalmic innovative drugs, industry chain collaboration, and empowering eye health through "New Quality Productive Forces". Dr. Liu Datao engaged in an in-depth exchange with renowned experts including Academician Fan Xianqun from Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Academician Wang Ningli from Beijing Tongren Hospital, CMU, Professor Sun Xinghuai from Eye & ENT Hospital of Fudan University, Professor Xu Xun from the First People's Hospital Affiliated with Shanghai Jiao Tong University, and Professor Lin Haotian from Zhongshan Ophthalmic Center (ZOC) of Sun Yat-sen University.

Currently, clinical practice places higher demands on ophthalmic new drugs, with urgent need for innovative products that are more effective, longer-lasting, easier to administer, and more accessible. Dr. Liu Datao emphasized that meeting clinical needs is fundamental to drug development, stressing that innovation requires deeper integration beyond traditional "industry-academia-research" models to include clinical practice.

Age-related diseases are a key strategic focus area for Mabwell, with ophthalmic diseases being a significant component within this category. As an innovative-driven pharmaceutical company with a fully integrated industry chain, Mabwell maintains long-term, close collaborations with universities and hospitals. Leveraging tools like AI, the company continuously accelerates R&D and the translation of innovative drug discoveries into treatments. In concluding his remarks, Dr. Liu Datao expressed his vision that the future will see more ophthalmic innovative drugs in China—delivering better efficacy capable of entering developed markets globally while enabling domestic patients to access treatments at a lower cost burden.